Clinical Trial Agreement delays often surface late, but affect start-up early.
For emerging biotech teams, the impact can be significant:
This playbook explains where delays come from and what organizations can do to improve speed, predictability, and execution discipline.
For biotech teams preparing for first ex-US studies, scaling site activation, or dealing with delays in contract execution.
• Why CTA execution has become a strategic study start-up issue
• Why the US remains highly variable despite market maturity
• What changes when biotech teams expand beyond the US
• What Europe’s contracting landscape reveals about delay and opportunity
• Lessons from Germany, France, the Netherlands, and Poland
• The 8 root causes of CTA delay across regions
• The 7 levers of faster, more predictable CTA execution
• Practical steps biotech teams can take now
Contract and budget negotiations are the #1 study start-up challenge in Europe
In 75% of European Member States, CTA execution takes more than 90 days
Europe aims for two-thirds of clinical trials to begin recruiting within 200 days from application submission
Faster regulatory review alone will not solve start-up delay if contracting remains slow
This makes contracting not just a legal issue, but a strategic operational issue for biotech teams building or scaling clinical development programs.
Also coming soon:
A cross-functional roundtable for biotech legal, regulatory/start-up, and clinical operations leaders:
Faster Contracts, Faster Activation
Be the first to hear when registration opens >> Follow us on LinkedIn